The quality of life in patients with hypertension is considered to be impaired mainly by side effects of antihypertensive drug therapy. Since balloon angioplasty for renal artery stenosis has a medication-sparing effect, it may lead to an improvement in quality of life. The objective of the study is to compare the effect of antihypertensive drug therapy and balloon angioplasty on quality of life in patients with hypertension and renal artery stenosis. We compared the quality of life in 56 patients randomised to balloon angioplasty to that in 50 patients randomised to antihypertensive drug therapy after 3 and 12 months of follow-up. Quality of life was measured using a questionnaire on physical symptoms associated with hypertension and antihypertensive drugs, and two generic health questionnaires (MOS Survey and EuroQol instrument). After follow-up, the patients who underwent angioplasty used less antihypertensive drugs than the patients who were treated with antihypertensive drugs only (mean7s.d., 1.970.9 vs 2.571.0 drugs after 3 months, P ¼ 0.002). They reported similar physical complaints, however, and a similar quality of life. The results after 12 months of follow-up were the same. In conclusion, for patients with hypertension and renal artery stenosis, the decrease in antihypertensive medication after intervention is too small to lead to a detectable improvement in quality of life.
Introduction
Health-related quality of life is often studied as an outcome of clinical research. 1 Treatment of a clinical condition may improve the quality of life in patients, but it may also decrease the quality of life due to side effects or complications. Hypertension, especially in the mild-to-moderate stages, generally is an asymptomatic condition. The quality of life of patients with hypertension can be affected, however, by concomitant diseases and labelling the patients with the diagnosis of hypertension. 2, 3 Moreover, numerous randomised clinical trials have shown that the quality of life can be impaired by side effects of antihypertensive drugs (Table 1) . 4, 5 Physical complaints such as headache, dizziness, nausea, drowsiness, diarrhea, and impotence are commonly acknowledged side effects of antihypertensive drugs. 6 Also, some of these drugs have been associated with psychological side effects, such as depression. 4 The objective of this study was to assess the effect of treatment on the quality of life in patients with hypertension and renal artery stenosis. Renal artery stenosis is a potential cause of hypertension. 7 Besides treatment with medication, patients with hypertension and renal artery stenosis can be treated by percutaneous transluminal renal angioplasty, which may lead to improvement or even cure of hypertension. 8 In our trial on diagnosis and treatment of patients with hypertension and renal artery stenosis, we found that the patients who were treated with angioplasty needed less antihypertensive drugs to control blood pressure than the patients who were treated with medication only 9 ( Table 1) . Since it has been demonstrated that patients who use less antihypertensive medication report a better health status, 10 the patients in our trial who received angioplasty may have experienced an improvement in their quality of life compared to the patients who received medication only.
Patients and methods

Patients
We compared quality of life of the patients who participated in the Dutch Renal Artery Stenosis Intervention Cooperative ('DRASTIC') study. 11 The trial was designed to identify patients with hypertension caused by renal artery stenosis and to evaluate their treatment. The therapeutic phase of the study involved 106 patients with drug-resistant hypertension (defined as diastolic blood pressure of 95 mmHg or more despite a standardised regimen of two antihypertensive drugs on three consecutive visits) and angiographically proven atherosclerotic renal artery stenosis of 50% or more. The patients were randomly allocated to balloon angioplasty (n ¼ 56) or to increased antihypertensive drug therapy (n ¼ 50). 9 The primary outcome of the trial was diastolic blood pressure. Quality of life was measured as a secondary outcome measure.
Quality of life
Quality of life was measured at baseline and after 3 and 12 months of follow-up. At the baseline measurement, which was performed during the diagnostic phase of the trial, the patients were aware that they were suspected of renal artery stenosis, although the final diagnosis had not been confirmed as yet by renal angiography. Quality of life was measured by means of three questionnaires. The first questionnaire was a validated Dutch version of a questionnaire for recording physical symptoms associated with hypertension or antihypertensive treatment and the effect of treatment on lifestyle. 12, 13 The second questionnaire was a validated Dutch version of the 'MOS Short-form General Health Survey' (MOS Survey). 14, 15 This generic health questionnaire measures six dimensions of quality of life: physical functioning, role functioning, social functioning, psychological wellbeing, health perceptions, and pain. Scores on these scales range between 0 and 100, with higher scores reflecting a better health. The third questionnaire was a validated Dutch version of the 'EuroQol' instrument. 16 This generic health questionnaire measures the ability to walk, the ability to perform daily activities, depression, anxiety, and pain on a 3-point scale. The scores on these aspects of quality of life are combined to describe general health status, which can be linked to a preference (utility) for the health status obtained from the general population. 17, 18 The utilities range between 0 (worst imaginable health status) and 100 (best imaginable health status).
Data analysis
We used regression analysis to compare quality of life between the patients randomised to angioplasty or drug therapy after 3 and 12 months of follow-up. In the analyses, the scores at 3 or at 12 months were used as the dependent variable, and treatment group (angioplasty or medication) as the independent variable. Quality of life scores before randomisation were entered as a covariate into the regression models to correct for baseline differences between the treatment groups. Quality of life comparisons after 3 months of follow-up involved the entire patient sample: 56 patients randomised to angioplasty were compared to 50 patients randomised to antihypertensive medication. Quality of life comparisons after 12 months involved the 28 patients of the medication group who received only medication throughout the study period. The other 22 patients, who were randomised to medication, were excluded from the 12-month analysis because they had received angioplasty after 3 months because of inadequate blood pressure control or because of a decline in renal function. Comparisons over time within patient groups were tested with the paired Student's t-test.
Results
Clinical outcome measures
The treatment groups were comparable with regard to age and sex, and with regard to blood pressure and the number of antihypertensive drugs at the (Table 2) . After 3 months of follow-up, the treatment groups had similar blood pressure levels. The patients in the angioplasty group, however, used less antihypertensive drugs than the patients in the drug therapy group (mean7s.d., 1.970.9 and 2.571.0 drugs, respectively; P ¼ 0.002). After 12 months, the blood pressure levels of the angioplasty group still were similar to those of the patients who were treated with antihypertensive medication only. Again, the angioplasty group used less drugs than the patients who were treated with medication only (1.970.9 and 2.470.8 drugs, respectively; P ¼ 0.002) ( Table 2) .
Quality of life
Quality of life before randomisation was comparable between the treatment groups (P40.30 for all quality of life scales, Table 3 ). After 3 and 12 months of follow-up, the number of physical complaints in the angioplasty group seemed to have decreased more than in the drug therapy group, but the differences were not statistically significant (P40.09). For the generic questionnaires (EuroQol index and scales of the MOS Survey), the average scores after 3 and 12 months of follow-up were similar to the baseline measurement or had improved in both treatment groups (Table 3 ). No differences between the treatment groups in change in these quality of life scores after follow-up could be demonstrated after correction for the baseline scores (P40.10), except for the MOS-social functioning scale. The difference in change in scores on the latter scale was borderline significant at both 3 and 12 months (P ¼ 0.06 and 0.04, respectively), but at 3 months the angioplasty group had the better scores, and at 12 months the drug therapy group.
Discussion
The quality of life in patients with hypertension is considered to be impaired mainly by side effects of antihypertensive drug treatment. 4 We hypothesized to find an improvement in quality of life for patients with hypertension and renal artery stenosis who were treated by balloon angioplasty compared to patients who received antihypertensive drug therapy only, because the patients who were treated by T0  T3-T0  T12-T0  T0  T3-T0  T12- The effect of treatment on hypertension and renal artery stenosis P Krijnen et al angioplasty needed less or even no drug therapy after intervention. 9 The patients in the angioplasty group did seem to have less physical complaints after 3 months of follow-up, but the difference was too small to be confirmed statistically. We also expected but did not find an improvement of the generic health measures in the angioplasty group compared to the drug therapy group. Apparently, the decrease in medication due to intervention, which amounted to less than one drug on average, was too small to lead to a meaningful and detectable improvement in the measures of quality of life that were used in our study.
In a large community-based population, it was found that patients with hypertension who used less antihypertensive medication reported a better health status. 10 Our data, however, did not confirm this finding. At baseline, the number of antihypertensive drugs was not statistically significantly associated with any of the quality of life scales, probably because there was little variation in the number of prescribed drugs. Although the patients in our study used up to five different antihypertensive drugs at the same time, the majority used two or three drugs (59 and 24% of the patients, respectively).
The comparison between the quality of life in the groups with and without percutaneous intervention after 3 months was straightforward. The comparison between the treatment groups after 12 months of follow-up, however, was complicated by the fact that after 3 months of follow-up nearly half of the 50 patients who were randomised to drug therapy underwent angioplasty because of unsatisfactory blood pressure control or a decline of renal function. For the comparison at 12 months, we reported the results only for the 28 patients in the drug therapy group who received nothing but medication throughout the entire study period. Compared to the patients who were allocated to drug therapy but underwent angioplasty after 3 months, these patients were clinically better off at baseline with respect to blood pressure and medication use. 9 These patients also seemed to be somewhat better off with regard to the number of reported physical complaints and general health status, although this could not be confirmed statistically due to the small number of patients with nonmissing data in each group.
In conclusion, the medication sparing effect of intervention in patients with hypertension and renal artery stenosis is too small to lead to a meaningful improvement in quality of life for these patients.
